MedTrace Logo

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

NCT00515164 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2011-10-24

No results posted yet for this study

Summary

The purpose of this study it to evaluate the efficacy and safety of the 20 mL BLVR System in patients with advanced upper lobe predominant emphysema.

Conditions

Interventions

DRUG

Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel

20 mL Hydrogel

Sponsors & Collaborators

  • Aeris Therapeutics

    lead INDUSTRY

Principal Investigators

  • Geoffrey McLennan, MD · University of Iowa Hospitals & Clinics, Iowa City, IA

  • Charlie Strange, MD · Medical University of South Carolina

  • Mark Gotfried, MD · Pulmonary Associates, Phoenix, AZ

  • Mark Krasna, MD · St Joseph's Medical Center, Towson, MD

  • Sanjiv Tewari, MD · Akron Medical Center, Akron, OH

  • Gerard Criner, MD · Temple University Lung Center, Philadelphia, PA

  • William Leeds, DO · Veritas Clinical Specialties, Topeka, KS

  • Thomas Gildea, MD · Pulmonary, Allergy & Critical Care Medicine, Cleveland Clinic, Cleveland, OH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-04-30
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515164 on ClinicalTrials.gov